Formulation and Evalution of Transdermal Patch of Simvastatin

A simvastatin transdermal patch is a drug delivery system designed to deliver Simvastatin through the skin in a controlled and sustained manner. It is developed as an alternative to oral tablets, which have low bioavailability due to extensive first-pass metabolism in the liver. The patch typically contains polymers such as HPMC or Eudragit that help regulate drug release over time. By bypassing the gastrointestinal tract, it reduces side effects and maintains more consistent plasma drug levels. Simvastatin patches are mainly studied for the treatment of hyperlipidemia, aiming to improve patient compliance and therapeutic effectiveness. Overall, this system offers advantages like prolonged drug action, reduced dosing frequency, and better control of cholesterol levels, although it is still largely in the research and development stage The patch can be prepared using the solvent casting method with different polymers to achieve optimal mechanical strength, drug permeability, and adhesive properties. In vitro drug release studies are performed using Franz diffusion cells to evaluate the rate and extent of simvastatin permeation through synthetic membranes as well as excised animal skin. Various physicochemical characteristics, including thickness, tensile strength, moise content, and uniformity of drug content, are also assessed. The results indicate that the optimized formulation provides a sustained drug release over a period of 24 hours, along with effective skin permeation and a minimal lag time. The study concludes that a simvastatin -loaded transdermal patch represents a practical and efficient drug delivery system for the treatment of inflammatory conditions, offering a non-invasive and patient-friendly alternative.